Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745513 | 0.85 | CA1 (0.40) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL29057572 | 0.85 | CA1 (0.35) | CA1CA2CA12CA9LMNA | |
| SCHEMBL29057573 | 0.85 | CA1 (0.35) | CA1CA2CA12CA9LMNA | |
| SCHEMBL29057615 | 0.83 | PPM1B (0.39) | SMN1; SMN2CA1CA2CA12CA9 | |
| SCHEMBL29057613 | 0.83 | PPM1B (0.39) | SMN1; SMN2CA1CA2CA12CA9 | |
| SCHEMBL29991916 | 0.83 | PPP5C (0.43) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL419733 | 0.83 | CA1 (0.42) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL25940510 | 0.82 | MAPT (0.34) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL2705851 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL8914013 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4236937-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093850-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093849-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-7759343-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759343-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7462616-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462616-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | HTR2A, HTR5A, HTR1A | ALDH1A1 1144/4885SMN1; SMN2 2192/4885CA1 4241/4885 |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | ALDH1A1 768/4885SMN1; SMN2 2147/4885CA1 4814/4885 |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | ALDH1A1 3629/4885SMN1; SMN2 4350/4885CA1 3966/4885 |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | PLK2, CDK2, MAP3K15 | ALDH1A1 3629/4885SMN1; SMN2 4350/4885CA1 3966/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | ALDH1A1 873/4885SMN1; SMN2 1918/4885CA1 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.